{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:14:39Z","timestamp":1762866879319},"reference-count":53,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2016,7,13]],"date-time":"2016-07-13T00:00:00Z","timestamp":1468368000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Fundamemntal Clinical Pharma"],"published-print":{"date-parts":[[2016,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The aim of this study was to describe bisphosphonate\u2010related osteonecrosis of the jaw (<jats:styled-content style=\"fixed-case\">BRONJ<\/jats:styled-content>) in the French national pharmacovigilance database. <jats:styled-content style=\"fixed-case\">BRONJ<\/jats:styled-content> was identified with the standardized <jats:styled-content style=\"fixed-case\">MedDRA<\/jats:styled-content> query (<jats:styled-content style=\"fixed-case\">SMQ<\/jats:styled-content>) \u2018osteonecrosis\u2019 among all data from 1985 to 31 December 2014. Because this <jats:styled-content style=\"fixed-case\">SMQ<\/jats:styled-content> was not specific to the jaw localization, selection of cases based on anatomy was performed after data extraction. For each case, demographic and medical information was analysed, as well as data about notification (year of notification, year of occurrence, outcome, seriousness). Known associated factors for <jats:styled-content style=\"fixed-case\">BRONJ<\/jats:styled-content> were also documented: dentoalveolar surgery, glucocorticoids, chemotherapy, anti\u2010angiogenics, denosumab. Among 1404 <jats:styled-content style=\"fixed-case\">SMQ<\/jats:styled-content> notifications, 663 were located in the jaws and 629 were associated with bisphosphonate use. <jats:styled-content style=\"fixed-case\">BRONJ<\/jats:styled-content> reported in the database mainly affected women (<jats:italic>n<\/jats:italic> = 443, 71%) with an oncological indication (<jats:italic>n<\/jats:italic> = 440, 70%). <jats:styled-content style=\"fixed-case\">BRONJ<\/jats:styled-content> was considered as serious in 91%. Outcome was unfavourable for 92% of cases. Associated factors were identified for 70% of the patients. A peak of notification was noted in 2014 (13% of all cases), but on analysis by year of occurrence instead of by year of notification, this peak disappeared. <jats:styled-content style=\"fixed-case\">SMQ<\/jats:styled-content> \u2018osteonecrosis\u2019 appears to be an adequate tool to analyse <jats:styled-content style=\"fixed-case\">BRONJ<\/jats:styled-content> in a pharmacovigilance database.<\/jats:p>","DOI":"10.1111\/fcp.12211","type":"journal-article","created":{"date-parts":[[2016,6,17]],"date-time":"2016-06-17T14:56:48Z","timestamp":1466175408000},"page":"450-458","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Bisphosphonate\u2010related osteonecrosis of the jaw: data from the French national pharmacovigilance database"],"prefix":"10.1111","volume":"30","author":[{"given":"Paul","family":"de Boissieu","sequence":"first","affiliation":[{"name":"Department for Pharmacovigilance and Pharmacoepidemiology Reims University Hospital Avenue du General Koenig 51100 Reims France"},{"name":"Faculty of Medecine University of Reims Champagne\u2010Ardenne EA 3797 Reims France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Gaboriau","sequence":"additional","affiliation":[{"name":"Pharmacovigilance regional Centre Medical Pharmacology Lille University Hospital Lille France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurore","family":"Morel","sequence":"additional","affiliation":[{"name":"Department for Pharmacovigilance and Pharmacoepidemiology Reims University Hospital Avenue du General Koenig 51100 Reims France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Trenque","sequence":"additional","affiliation":[{"name":"Department for Pharmacovigilance and Pharmacoepidemiology Reims University Hospital Avenue du General Koenig 51100 Reims France"},{"name":"Faculty of Medecine University of Reims Champagne\u2010Ardenne EA 3797 Reims France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,7,13]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.4065\/83.9.1032"},{"key":"e_1_2_9_3_1","first-page":"956","article-title":"Osteonecrosis of the jaw in a patient with bisphosphonates therapy","volume":"28","author":"Germain M.L.","year":"2005","journal-title":"Drug Saf."},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0278-2391(03)00566-4"},{"key":"e_1_2_9_5_1","unstructured":"Food and Drug Administration.Oncologic Drugs Advisory Committee Meeting \u2013 March 4 2005. Available from:http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/05\/questions\/2005-4095Q2_02_Zometa-Aredia-Questions.pdf(accessed 02 October 2015)"},{"key":"e_1_2_9_6_1","unstructured":"European Medicines Agency.CHMP Assessment report on bisphosphonates and osteonecrosis of the jaw \u2013 September 2009. Available from:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Report\/2010\/01\/WC500051428.pdf(accessed 02 October 2015)"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2008.12.003"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2009.01.006"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2014.04.031"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.080205"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/hed.20941"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.5125\/jkaoms.2013.39.1.9"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.8670"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.21.9584"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.4317\/medoral.18076"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2014.951329"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70305-X"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(85)90918-3"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199920020-00002"},{"key":"e_1_2_9_20_1","unstructured":"MedDRA Maintenance and Support Services Organisation.Introductory Guide for Standardised MedDRA Queries (SMQs) version 15.0. Available from:http:\/\/www.meddra.org\/sites\/default\/files\/guidance\/file\/smq_intguide_15_0_english.pdf(accessed 02 October 2015)"},{"key":"e_1_2_9_21_1","unstructured":"Council for International Organizations of Medical Sciences.CIOMS form. Available from:http:\/\/cioms.ch\/index.php\/cioms-form-i(accessed 5 October 2015)"},{"key":"e_1_2_9_22_1","unstructured":"Food and Drug Administration.Reporting serious problems to FDA \u2013 what is a serious adverse event?Available from:http:\/\/www.fda.gov\/safety\/medwatch\/howtoreport\/ucm053087.htm(accessed 12 October 2015)"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2016.02.010"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2693"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.2515\/therapie:2007003"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-010-0907-7"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2009-0115"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.28.5.667"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00784-009-0300-6"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105195"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62344-6"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-010-0882-1"},{"key":"e_1_2_9_33_1","first-page":"968","article-title":"Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: Evidence of increased risk after treatment with zoledronic acid","volume":"91","author":"Dimopoulos M.A.","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0278-2391(03)00720-1"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2010.05835.x"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coms.2015.06.001"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2405"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr435"},{"key":"e_1_2_9_39_1","unstructured":"Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9.Lettres aux professionnels de sant\u00e9. Recommandations sur la prise en charge bucco\u2010dentaire des patients trait\u00e9s par bisphosphonates. Available from:http:\/\/www.ansm.sante.fr\/content\/download\/11694\/140950\/version\/2\/file\/lp071203.pdf(accessed 4 November 2015)"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.040305"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2009.10.010"},{"key":"e_1_2_9_42_1","unstructured":"MedDRA Maintenance and Support Services Organisation.SMQ status \u2013 MedDRA. Available from:www.meddra.org\/sites\/\u2026\/smq_status_mar_2015.xlsx(accessed 4 November 2015)"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-014-0187-2"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200730100-00007"},{"key":"e_1_2_9_45_1","unstructured":"ANSM: Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9.Lettre aux professionnels de sant\u00e9: acide zol\u00e9dronique\/pamidronate de sodium et ost\u00e9on\u00e9crose de la m\u00e2choire. Available from:http:\/\/www.ansm.sante.fr\/S-informer\/Informations-de-securite-Lettres-aux-professionnels-de-sante\/Acide-zoledronique-pamidronate-de-sodium-et-osteonecrose-de-la-machoire(accessed 4 November 2015)"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2009.01.009"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200629050-00003"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1997.05417.x"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.3109\/00016357.2013.764007"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02504.x"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.2515\/therapie\/2014035"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S75761"},{"key":"e_1_2_9_53_1","unstructured":"International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline \u2010 Post\u2010approval safety data management: definitions and standards for expedited reporting. Available from:http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E2B\/Step4\/E2B_R2__Guideline.pdf(accessed 16 November 2015)"},{"key":"e_1_2_9_54_1","unstructured":"EudraVigilance.Pharmacovigilance in EEA. Available from:https:\/\/eudravigilance.ema.europa.eu\/human\/textforIME.asp(accessed 16 November 2015)"}],"container-title":["Fundamental &amp; Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ffcp.12211","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/fcp.12211","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T06:33:26Z","timestamp":1696314806000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/fcp.12211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,13]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["10.1111\/fcp.12211"],"URL":"https:\/\/doi.org\/10.1111\/fcp.12211","archive":["Portico"],"relation":{},"ISSN":["0767-3981","1472-8206"],"issn-type":[{"value":"0767-3981","type":"print"},{"value":"1472-8206","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,13]]},"assertion":[{"value":"2015-12-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-06-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-07-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}